QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wu, J. K Articles by Harris, M. T Search for Related Content PubMed PubMed Citation Articles by Wu, J. K Articles by Harris, M. T

DRUG INFORMATION ROUNDS

Use of Leflunomide in the Treatment of Polyomavirus BK–Associated Nephropathy

Pharmacy Practice Resident, Department of Pharmacy, Duke University Hospital, Durham, NC

Matthew T Harris, PharmD BCPS

Abdominal Transplant Clinical Pharmacist, Director of PGY2 Solid Organ Transplant Residency, Department of Pharmacy, Duke University Hospital

Reprints: Dr. Wu, Department of Pharmacy, Duke University Hospital, DUMC Box 3089, Durham, NC 27710, fax 919/681-2741, judy.wu{at}duke.edu

OBJECTIVE: To review the available literature describing the use of leflunomide for the treatment of polyomavirus BK–associated nephropathy (BKVAN) in renal transplant recipients.

DATA SOURCES: Relevant literature was obtained through MEDLINE (1950–May 2008) and Science Citation Index Expanded (1900–May 2008) by using search terms leflunomide, Arava, polyomavirus, polyoma, BK virus, and transplant. Additional articles were identified through a manual search of the reference lists of the articles obtained.

STUDY SELECTION AND DATA EXTRACTION: All articles that were written in English and discussed leflunomide use for BKVAN in renal transplant recipients were evaluated. Case reports and in vitro studies were included in this review.

DATA SYNTHESIS: BKVAN has emerged as a problematic infectious complication with limited treatment options in renal transplant recipients. Leflunomide, used off-label for refractory BKVAN, is postulated to possess both antiviral and immunosuppressive properties. Two in vitro culture studies, 5 case reports/series, 2 retrospective cohort studies, and 3 prospective observational trials that described leflunomide use in BKVAN were identified. Available literature suggests that leflunomide at target blood concentrations of around 40 mg/L, in addition to immunosuppressive reduction, reduces BK viremia/viruria and graft failure, with few dose-limiting adverse events. It is highly recommended that routine complete blood cell counts, hepatic function panels, and drug concentrations be monitored to detect toxicity.

CONCLUSIONS: Leflunomide appears to be promising as adjunctive treatment of BKVAN in renal transplant patients. Due to the lack of controlled randomized trials, however, use of leflunomide as first-line treatment cannot be routinely recommended.

Key Words: BK virus, leflunomide, polyomavirus, renal transplant

Published Online, October 28, 2008. www.theannals.com, DOI 10.1345/aph.1L180